Myasthenia Gravis Panel 3

Myasthenia Gravis Panel 3

Test Code

10211
86041, 86042, 86043, 86255
10211
86041, 86042, 86043, 86255
Not offered in Quest Diagnostics Nichols Institute (IFD) – San Juan Capistrano. Please provide SERVICE AREA INFORMATION to find available tests you can order.
In-home collection may be available in your area for purchase through Quest Mobile.

Clinical Significance

Myasthenia Gravis Panel 3 -

Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody. There is a strong correlation between the presence of striated muscle antibody and the presence of thymoma.

Test Details

Includes

  • Acetylcholine Receptor Binding Antibody
    Acetylcholine Receptor Blocking Antibody
    Acetylcholine Receptor Modulating Antibody
    Striated Muscle Antibody with Reflex to Titer

    If Striated Muscle Antibody Screen is positive, then Striated Muscle Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

Methodology

See individual tests

Assay Category

Acetylcholine Receptor Modulating Antibody: This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Reference Range(s)

See Laboratory Report

LOINC® Codes, Performing Laboratory

Acetylcholine Receptor Binding Antibody
Acetylcholine Receptor Blocking Antibody
Acetylcholine Receptor Modulating Antibody
Striated Muscle Antibody with Reflex to Titer

If Striated Muscle Antibody Screen is positive, then Striated Muscle Antibody Titer will be performed at an additional charge (CPT code(s): 86256).

Methodology

See individual tests
Acetylcholine Receptor Modulating Antibody: This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Reference Range(s)

See Laboratory Report

Preferred Specimen(s)

2 mL serum

Minimum Volume

0.8 mL

Transport Container

Transport tube

Transport Temperature

Room temperature

Specimen Stability

  • Room temperature: 4 days
  • Refrigerated: 14 days
  • Frozen: 30 days

Reject Criteria

See individual tests

Setup Schedule

2 mL serum
0.8 mL
Transport tube

Room temperature

Room temperature: 4 days
Refrigerated: 14 days
Frozen: 30 days
See individual tests
Not offered in Quest Diagnostics Nichols Institute (IFD) – San Juan Capistrano. Please provide SERVICE AREA INFORMATION to find available tests you can order.
In-home collection may be available in your area for purchase through Quest Mobile.
Test Details

Clinical Significance

Test Resources

Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.

The CPT codes provided are based on AMA guidance and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

This material contains content from LOINC® (http://loinc.org). The LOINC Table, LOINC Table Core are copyright © 1995-2019, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license.

The tests listed by specialty and category are a select group of tests offered. For a complete list of Quest Diagnostics tests, please adjust the filter options chosen, or refer to our Directory of Services.